PAVmed (PAVM) Common Equity (2015 - 2025)

PAVmed's Common Equity history runs 11 years deep, the most recent figure standing at $22.3 million for Q4 2025.

• In Q4 2025, Common Equity rose 417.08% year-over-year to $22.3 million; the TTM figure through Dec 2025 stood at $22.3 million (up 417.08% YoY), while the FY2025 annual figure was $22.3 million, up 417.08% from the prior year.
• Common Equity was $22.3 million for Q4 2025 at PAVmed, down from $22.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $79.4 million in Q4 2021 to a low of -$24.0 million in Q4 2023.
• Historically, Common Equity has averaged $19.8 million across 5 years, with a median of $22.4 million in 2025.
• The sharpest annual moves came in 2021 and 2024: Common Equity soared 16890.27% in 2021, then plunged 2146.02% in 2024.
• A 5-year view of Common Equity shows it stood at $79.4 million in 2021, then sank by 86.23% to $10.9 million in 2022, then slumped by 319.66% to -$24.0 million in 2023, then surged by 70.72% to -$7.0 million in 2024, then jumped by 417.08% to $22.3 million in 2025.
• The last three Common Equity figures came in at $22.3 million (Q4 2025), $22.5 million (Q3 2025), and $28.2 million (Q2 2025), per Business Quant data.